Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.
Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer (CRC).
The investigational antibody-drug conjugate patritumab deruxtecan utilizes a similar mechanism of action as fam-trastuzumab deruxtecan-nxki (Enhertu), says Grothey. However, patritumab deruxtecan targets HER3 and trastuzumab deruxtecan targets HER2. Notably, patritumab deruxtecan may have greater utility compared with trastuzumab deruxtecan because HER3 is commonly overexpressed on CRC cells and HER2 has limited expression, Grothey explains.
The agent is being evaluated for safety and efficacy in an ongoing phase 2 trial (NCT04479436) in patients with advanced or metastatic CRC, concludes Grothey.